Down syndrome is the most common genetic cause of intellectual disability in the world.
Yet for decades, the question of why (why do neurons connect differently, why does cognition develop along a distinct path, and why does Alzheimer’s disease appear so frequently in people with Down syndrome) remained largely unanswered.
Neuroscientists are now investigating the molecular and cellular mechanisms behind Down syndrome at an unprecedented level of detail, and the findings are pointing toward real therapeutic targets.
The Brain Research Foundation has been part of this work, funding seed grants that examine how neurons form, how connections break down, and what can be done about it.
This article brings together what is currently known about Down syndrome and the brain, grounded in BRF-funded research and the neuroscience it represents.
What Is Down Syndrome?
Down syndrome is a chromosomal condition caused by the presence of a third copy of chromosome 21; a state known as Trisomy 21. This additional genetic material alters development throughout the body, but its effects on the brain are among the most significant and most studied.
As we’ve explored in funded research, Down syndrome is the most common genetic form of intellectual disability caused by a birth defect, and there is currently no effective treatment for the neurological aspects of the condition.
That gap is precisely why foundational neuroscience research in this area matters.
How Does Down Syndrome Affect the Brain?
Down syndrome does not affect one isolated region of the brain. Its effects are neurodevelopmental, meaning they begin during the earliest stages of brain formation and continue to evolve throughout a person’s lifetime.
BRF-funded research at the University of Michigan identified defective development of the cerebral cortex (the region of the brain responsible for higher-order functions, including reasoning, language, and decision-making) as a core feature of the condition.
Abnormalities in how cortical neurons form and organise during development are now considered central to understanding intellectual disability in Down syndrome.
The downstream effects of this include:
- Cognitive deficits: affecting attention, working memory, reasoning, and problem-solving
- Language development delays: typically apparent from the first months of life
- Motor development differences: impacting physical milestones and coordination
- Learning and memory difficulties: reflecting disrupted synaptic function and neural connectivity
These are not uniform (individuals with Down syndrome vary considerably in the degree to which each area is affected), but the underlying mechanisms share a common origin in how neurons develop, connect, and communicate.
What Chromosome Causes Down Syndrome?
Down syndrome is caused by an extra copy of chromosome 21, giving affected individuals three copies instead of the usual two, hence the clinical term Trisomy 21.
Chromosome 21 carries a number of genes that, when present in three copies rather than two, alter the balance of proteins and regulatory molecules in the developing brain. One of the most extensively studied is the Down Syndrome Cell Adhesion Molecule, or DSCAM.
What Is the Role of DSCAM in Down Syndrome?
A BRF Seed Grant awarded to Dr Bing Ye at the University of Michigan investigated the consequences of elevated DSCAM levels in the developing brain. The research found that when there is too much DSCAM during brain development, neurons fail to form properly.
The Ye lab also identified a key molecular mediator of this effect — a finding that opens the door to the design of targeted therapeutic strategies.
This research moved from fruit fly models (where genetic tools are particularly powerful) to mouse models, enabling the team to observe how excessive DSCAM levels lead to defective cortical development in the mammalian brain. The goal was not just to describe the problem but to identify targets that could one day be addressed pharmacologically.
How Does Down Syndrome Affect Synaptic Function?
One of the most important recent developments in Down syndrome neuroscience is the focus on synapses — the connections between neurons through which all brain communication flows. In individuals with Down syndrome, synapses are both fewer in number and altered in how they function.
A 2023 BRF Seed Grant awarded to Dr Andre M. M. Sousa at the University of Wisconsin-Madison directly investigates this problem. Dr Sousa’s research focuses on a gene called Cerebellin-2, which is critical for the formation and maintenance of neuronal connections.
What Is Cerebellin-2 and Why Does It Matter in Down Syndrome?
Dr Sousa’s preliminary findings revealed that Cerebellin-2 levels in the neurons of individuals with Down syndrome are greatly reduced during the critical developmental period when synapses are forming.
His hypothesis: this reduction is the primary cause of the synaptic deficits observed in Down syndrome, both the lower number of connections and their impaired ability to communicate.
The research uses stem cells from donors with and without Down syndrome to study how reduced Cerebellin-2 expression affects synapse formation, and whether restoring normal Cerebellin-2 levels in Down syndrome neurons can re-establish proper synaptic function.
If it can, Cerebellin-2 becomes a viable therapeutic target: a specific molecular lever that, when adjusted, could partially restore the neural architecture underlying learning and memory.
Why Do Synaptic Problems Begin So Early?
The appearance of cognitive and motor deficits within the first months of life points to the fact that synaptic alterations in Down syndrome are not secondary complications — they are developmental in origin. Dr Sousa’s research describes these as alterations that appear during the earliest stages of brain development, which means any effective therapeutic approach will likely need to act early in life to have the greatest impact.
Why Do People With Down Syndrome Get Alzheimer’s Disease?
One of the most significant and medically urgent aspects of Down syndrome is its connection to Alzheimer’s disease.
People with Down syndrome face a dramatically elevated lifetime risk of developing Alzheimer’s, and they tend to develop it at an earlier age than the general population, typically in their 50s, though the brain changes begin earlier still.
This is not a coincidence. It is a direct consequence of Trisomy 21.
What Is the Link Between Chromosome 21 and Alzheimer’s Disease?
Chromosome 21 contains the gene for amyloid precursor protein (APP). Because individuals with Down syndrome carry three copies of chromosome 21, they produce elevated levels of APP throughout their lives.
APP is the protein that, when processed in certain ways, generates the amyloid-beta fragments that form the plaques associated with Alzheimer’s disease.
The overexpression of APP in Down syndrome creates a lifelong environment of elevated amyloid production, effectively accelerating the biological timeline toward Alzheimer ‘s-type neurodegeneration.
BRF research on synaptic vesicle biogenesis, including a seed grant examining synaptic vesicle recycling linked to Alzheimer’s, Parkinson’s, and Down syndrome, highlights how impaired vesicle recycling (the mechanism by which neurons replenish the chemical signals they use to communicate) connects these conditions at a molecular level.
Disruptions to this fundamental process affect learning and memory and are implicated in the neurodegenerative cascade observed in Alzheimer’s disease.
For a deeper understanding of dementia more broadly, our educational overview of dementia explains the types, symptoms, and research directions that apply across neurodegenerative conditions, including those that disproportionately affect the Down syndrome population.
How Is Down Syndrome Different From Other Genetic Causes of Intellectual Disability?
Down syndrome is the most common genetic cause of intellectual disability overall, but it is not the only one. Understanding how it differs from conditions like Fragile X syndrome helps clarify why the research approaches may differ as well.
Down Syndrome vs Fragile X Syndrome
While Down syndrome results from a chromosomal abnormality (an extra chromosome 21), Fragile X syndrome is caused by a mutation in a single gene — the FMR1 gene on the X chromosome. BRF has published both an overview of Fragile X syndrome and a more detailed article on the causes, symptoms, and latest neuroscience research of Fragile X syndrome, which together offer a useful comparison.
Key differences include:
- Cause: Down syndrome — extra chromosome 21 (Trisomy 21); Fragile X — FMR1 gene mutation on the X chromosome
- Inheritance: Down syndrome typically occurs as a de novo chromosomal event, not inherited in the traditional sense; Fragile X is inherited in an X-linked dominant pattern
- Alzheimer’s connection: Down syndrome carries a specific and direct elevated risk due to APP overexpression; Fragile X does not carry the same Alzheimer’s link
- Research targets: Down syndrome research is increasingly focused on DSCAM, Cerebellin-2, and synaptic formation; Fragile X research centres on the FMRP protein and its role in regulating synaptic protein synthesis
Both conditions involve synaptic dysfunction — the failure of neuronal connections to form and operate correctly — but the upstream causes and the specific molecular pathways are distinct.
What Are the Latest Research Developments for Down Syndrome?
Research into Down syndrome has accelerated significantly, driven by advances in single-cell genomics, stem cell technology, and a clearer understanding of the molecular pathways involved. Several threads are particularly active.
Synaptic Restoration as a Therapeutic Target
The work by Dr Sousa at Wisconsin-Madison represents one of the most promising current lines of enquiry. By identifying Cerebellin-2 dysregulation as a driver of synaptic deficiency in Down syndrome, and by testing whether restoring Cerebellin-2 expression in human neurons can re-establish normal connectivity, his team is working toward a specific, testable intervention.
This kind of study — moving from observation to molecular target to potential therapy — is exactly the type of work the BRF Seed Grant programme is designed to accelerate.
Cortical Development Research
Earlier BRF-funded work by Dr Bing Ye established that defective cerebral cortex development is a core mechanism in Down syndrome intellectual disability.
By moving from Drosophila to mouse models, that research demonstrated that elevated DSCAM levels disrupt cortical formation — a finding that has since informed broader research into neurodevelopmental disorders and potential points of intervention.
The Alzheimer’s–Down Syndrome Research Intersection
The overlap between Down syndrome and Alzheimer’s research is becoming an increasingly productive area of neuroscience. Because people with Down syndrome represent a population with highly predictable Alzheimer’s risk they offer a unique window into how amyloid accumulation begins and progresses over decades. This has implications not just for Down syndrome but for Alzheimer’s research more broadly.
Stem Cell Approaches
The use of stem cells derived from individuals with Down syndrome — as employed in Dr Sousa’s Cerebellin-2 research — allows scientists to study the condition in human neurons rather than relying entirely on animal models. This is significant because some molecular dynamics in the human brain differ meaningfully from those in rodent or insect models, and human stem cell-derived neurons provide a closer approximation of what is happening in the actual condition.
How Does Down Syndrome Research Benefit From Neuroscience Funding?
One of the realities of Down syndrome research is that it sits at the intersection of multiple fields — developmental neuroscience, genetics, cognitive neuroscience, and dementia research — and has historically required funding that can support early-stage, high-risk, exploratory work before larger grants become available.
That is the role that organisations like the Brain Research Foundation play. BRF’s Seed Grant programme provides funding to early-career and established researchers pursuing innovative neuroscience questions that may not yet be ready for major NIH funding. For every dollar BRF awards in seed grants, grantees secure on average $30 in follow-on funding from other programmes — meaning each BRF grant acts as a multiplier for the wider research ecosystem.
In the context of Down syndrome, this has meant funding the molecular genetics work of Dr Bing Ye in 2015, and the synaptic biology work of Dr Andre Sousa in 2023 — two different eras, two different tools, but the same fundamental question: what goes wrong in the Down syndrome brain, and what can science do about it?
If you want to support this work, visit BRF’s Get Involved page to learn how donations fund pioneering neuroscience research.
The Brain Research Foundation’s investment in this science — from early molecular studies to the latest synaptic biology — reflects a conviction that understanding the brain at its most fundamental level is the essential first step toward treatments that improve lives. To explore the full scope of BRF-funded neuroscience, visit the Education & News section or browse the complete Seed Grants archive.
